Zoetis’ (ZTS) Buy Rating Reaffirmed at Craig Hallum

Zoetis (NYSE:ZTS)‘s stock had its “buy” rating restated by stock analysts at Craig Hallum in a research report issued to clients and investors on Wednesday, The Fly reports. They currently have a $94.00 price target on the stock, up from their previous price target of $87.00. Craig Hallum’s price target would indicate a potential upside of 11.78% from the company’s previous close.

ZTS has been the subject of several other research reports. Citigroup reissued a “buy” rating and issued a $98.00 price target (up previously from $85.00) on shares of Zoetis in a research note on Thursday, April 19th. Hilliard Lyons cut Zoetis to a “neutral” rating in a research note on Thursday, April 19th. They noted that the move was a valuation call. Cantor Fitzgerald set a $90.00 price target on Zoetis and gave the company a “buy” rating in a research note on Tuesday. Morgan Stanley cut Zoetis from an “overweight” rating to an “equal weight” rating and set a $70.00 price target for the company. in a research note on Monday, March 19th. They noted that the move was a valuation call. Finally, Jefferies Group reissued a “buy” rating and issued a $96.00 price target on shares of Zoetis in a research note on Friday, April 13th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and thirteen have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $82.11.

How to Become a New Pot Stock Millionaire

Zoetis stock traded down $0.26 during trading hours on Wednesday, hitting $84.09. The stock had a trading volume of 314,952 shares, compared to its average volume of 2,679,411. The company has a current ratio of 3.85, a quick ratio of 2.55 and a debt-to-equity ratio of 2.77. The company has a market capitalization of $41,392.14, a PE ratio of 35.07, a P/E/G ratio of 1.89 and a beta of 0.96. Zoetis has a one year low of $55.08 and a one year high of $86.38.



Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, February 15th. The company reported $0.69 EPS for the quarter, beating the consensus estimate of $0.66 by $0.03. The firm had revenue of $1.46 billion during the quarter, compared to the consensus estimate of $1.40 billion. Zoetis had a return on equity of 65.96% and a net margin of 16.28%. The business’s quarterly revenue was up 14.3% on a year-over-year basis. During the same period last year, the company earned $0.47 earnings per share. analysts predict that Zoetis will post 3.04 earnings per share for the current fiscal year.

In related news, EVP Roxanne Lagano sold 35,663 shares of the firm’s stock in a transaction that occurred on Wednesday, February 21st. The stock was sold at an average price of $81.02, for a total transaction of $2,889,416.26. Following the completion of the sale, the executive vice president now owns 49,919 shares of the company’s stock, valued at $4,044,437.38. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Heidi C. Chen sold 7,383 shares of the firm’s stock in a transaction that occurred on Friday, March 16th. The stock was sold at an average price of $84.71, for a total value of $625,413.93. Following the sale, the insider now directly owns 20,162 shares of the company’s stock, valued at approximately $1,707,923.02. The disclosure for this sale can be found here. Insiders have sold 112,952 shares of company stock valued at $9,219,843 in the last ninety days. 0.35% of the stock is currently owned by insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ZTS. Robecosam AG grew its stake in Zoetis by 4.6% in the fourth quarter. Robecosam AG now owns 15,346 shares of the company’s stock valued at $1,111,000 after acquiring an additional 679 shares during the period. Daiwa Securities Group Inc. grew its stake in Zoetis by 4.3% in the fourth quarter. Daiwa Securities Group Inc. now owns 16,828 shares of the company’s stock valued at $1,212,000 after acquiring an additional 697 shares during the period. Sandy Spring Bank grew its stake in Zoetis by 2.3% in the fourth quarter. Sandy Spring Bank now owns 31,018 shares of the company’s stock valued at $2,235,000 after acquiring an additional 708 shares during the period. Penserra Capital Management LLC grew its stake in Zoetis by 18.6% in the fourth quarter. Penserra Capital Management LLC now owns 4,550 shares of the company’s stock valued at $327,000 after acquiring an additional 715 shares during the period. Finally, Advisory Services Network LLC grew its stake in Zoetis by 42.4% in the fourth quarter. Advisory Services Network LLC now owns 2,423 shares of the company’s stock valued at $175,000 after acquiring an additional 721 shares during the period. 92.45% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: This piece of content was posted by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US & international copyright & trademark legislation. The correct version of this piece of content can be viewed at https://stocknewstimes.com/2018/04/25/zoetis-zts-buy-rating-reaffirmed-at-craig-hallum.html.

About Zoetis

Zoetis Inc discovers, develops, manufactures, and markets veterinary vaccines and medicines in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

The Fly

Analyst Recommendations for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply